We combine leading protein engineering capabilities and deep insights into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes. Our pipeline is focused on inhalable Anticalin proteins to treat respiratory diseases locally and immuno-oncology multi-specifics tailored for the tumor microenvironment.
In our quest to provide solutions for patients, we are currently enrolling for our respiratory and immuno-oncology clinical trials.
In our quest to provide solutions for patients, we are currently enrolling for our respiratory and immuno-oncology clinical trials.
Services
At Pieris, we combine leading protein engineering capabilities and deep insights into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients.
Our proprietary Anticalin(R) technology based on human lipocalins - proteins that naturally bind and transport molecules throughout the body - forms the basis of our development focus to effect a local mechanism of action to address cancer and respiratory diseases.Our biologics have been validated in the clinic and by partnerships with leading pharmaceutical companies.
Our proprietary Anticalin(R) technology based on human lipocalins - proteins that naturally bind and transport molecules throughout the body - forms the basis of our development focus to effect a local mechanism of action to address cancer and respiratory diseases.Our biologics have been validated in the clinic and by partnerships with leading pharmaceutical companies.
Protein Engineering Leadership + Deep Understanding of Molecular Drivers of Disease = Novel Local-acting Therapies. Anticalin proteins are small, stable, modular, and inhalable molecules derived from human lipocalins - proteins that naturally transport molecules throughout the body.
These stable, modular proteins can be linked to other therapeutic modalities or each other to create multispecific and multifunctional drug candidates with a broad range of therapeutic applications.At Pieris, our expansive libraries contain more than 100 billion different Anticalin proteins, ensuring a candidate for almost any therapeutic target.
These stable, modular proteins can be linked to other therapeutic modalities or each other to create multispecific and multifunctional drug candidates with a broad range of therapeutic applications.At Pieris, our expansive libraries contain more than 100 billion different Anticalin proteins, ensuring a candidate for almost any therapeutic target.
Pieris Pharmaceuticals is currently enrolling patients in respiratory and immuno-oncology clinical trials. New treatments are made possible by volunteers who participate in clinical trials and we highly encourage and welcome your participation. Our Phase 2 study is designed to investigate the safety, tolerability, pharmacokinetics, and efficacy of multiple doses of PRS-060, a promising drug candidate being developed to treat asthma.
At Pieris, our mission is to develop life-changing therapeutics that will improve the lives of patients as well as providing a rewarding work environment that simultaneously improves the lives of our employees and their families. This vision guides everything we do. Pieris employees are enthusiastic and creative, and they enjoy working in a dynamic environment.
Reviews
Be the first to review Pieris Pharmaceuticals.
Write a Review
